In this prospective randomized , double-blind , placebo-controlled study , 380 CHB patients with PNALT were screened , 82 patients received biopsy and 43 patients met the HBV DNA and histology criteria and were randomly assigned to either an entecavir or placebo group for 52 weeks , with 22 and 21 in each group , respectively .